Faulds Gary, Rydén Mikael, Ek Ingvar, Wahrenberg Hans, Arner Peter
Department of Medicine, Huddinge University Hospital, Karolinska Institute, SE-141 86 Stockholm, Sweden.
J Clin Endocrinol Metab. 2003 May;88(5):2269-73. doi: 10.1210/jc.2002-021573.
Lipolytic catecholamine resistance in sc fat cells is observed in polycystic ovarian syndrome (PCOS). The mechanisms behind this lipolysis defect were explored in vitro; sc fat cells were obtained from 10 young, nonobese PCOS women and from 14 matched, healthy control women. Fasting plasma glycerol levels were reduced by one third in PCOS (P < 0.05). Adipocytes of PCOS women were about 25% larger than in the controls (P < 0.05) and had 40% reduced noradrenaline-induced lipolysis (P < 0.05), which could be attributed to a 10-fold decreased beta(2)-adrenoceptor sensitivity (P < 0.05) and low ability of cAMP to activate the protein kinase A (PKA)/hormone-sensitive lipase (HSL) complex (P < 0.05). In PCOS, the adipocyte protein content of beta(2)-adrenoceptors, HSL, and the regulatory II beta-component of PKA were 70%, 55%, and 25% decreased, respectively (P < 0.001); but there was no change in the amount of the catalytic subunit of PKA or of beta(1)-adrenoceptors. Thus, lipolytic catecholamine resistance of sc adipocytes in PCOS is probably attributable to a combination of decreased amounts of beta(2)-adrenergic receptors, the regulatory II beta-component of PKA, and HSL. This may cause low in vivo lipolytic activity and enlarged sc fat cell size and promote later development of obesity in PCOS.
在多囊卵巢综合征(PCOS)患者中观察到皮下脂肪细胞存在脂解性儿茶酚胺抵抗。我们在体外探究了这种脂解缺陷背后的机制;从10名年轻、非肥胖的PCOS女性和14名匹配的健康对照女性中获取皮下脂肪细胞。PCOS患者空腹血浆甘油水平降低了三分之一(P < 0.05)。PCOS女性的脂肪细胞比对照组大约大25%(P < 0.05),去甲肾上腺素诱导的脂解作用降低了40%(P < 0.05),这可归因于β(2)-肾上腺素能受体敏感性降低了10倍(P < 0.05)以及环磷酸腺苷(cAMP)激活蛋白激酶A(PKA)/激素敏感性脂肪酶(HSL)复合物的能力较低(P < 0.05)。在PCOS患者中,β(2)-肾上腺素能受体、HSL以及PKA的调节性IIβ亚基的脂肪细胞蛋白含量分别降低了70%、55%和25%(P < 0.001);但PKA催化亚基或β(1)-肾上腺素能受体的量没有变化。因此,PCOS患者皮下脂肪细胞的脂解性儿茶酚胺抵抗可能归因于β(2)-肾上腺素能受体、PKA的调节性IIβ亚基和HSL的量减少。这可能导致体内脂解活性降低和皮下脂肪细胞体积增大,并促进PCOS患者后期肥胖的发展。